Brief: Aravive To Present Promising Updated Data From Phase 2 Trial Of Batiraxcept In Combination With Cabozantinib In Clear Cell Renal Cell Carcinoma At ASCO 2023
25/05/2023 23:08
May 25 (Reuters) - Aravive Inc ARAV.O :
* ARAVIVE TO PRESENT PROMISING UPDATED DATA FROM PHASE 2
TRIAL OF
BATIRAXCEPT IN COMBINATION WITH CABOZANTINIB IN CLEAR CELL RENAL
CELL CARCINOMA AT ASCO 2023
Source text for Eikon: ID:nGNXdqYd4
Further company coverage: ARAV.O
((Reuters.Briefs@thomsonreuters.com;))